|
THE BENEFITS OF
Thalidomide
Thalidomide Diseases Uses
WHY
IS THALIDOMIDE USED
TODAY
IN
THE UK
About Myeloma: Introduction
Multiple
myeloma, a cancer of the plasma cell, is an incurable but
treatable disease. While a myeloma diagnosis can be
overwhelming, it is important to remember that there are
several promising, new therapies that are helping patients
live longer, healthier lives.
There are approximately 45,000 people in the United States
living with multiple myeloma and an estimated 14,600 new
cases of multiple myeloma are diagnosed each year.
This section will provide a detailed disease overview and
will discuss:
Initial diagnosis
Myeloma symptoms
Diagnostic tests
Prognostic indicators
Disease staging
An introduction to treatment options
In
addition to the information provided to you by your
physician, the information in this section will serve as an
invaluable resource as you begin to educate yourself about
the disease.
Website:
http://www.multiplemyeloma.org
UNDERSTANDING
MYELOMA
(Please
click on symbol below to view video)
.......................................
Celgene however
is the owner of the business process patents on components, which
will be essential elements of the new isotretinoin RiskMAP. Celgene
is not involved in the strengthened isotretinoin RiskMAP aside from
the patent negotiations.
In US the
U.S.
Food and Drug Administration 'FDA or USFDA' (an
agency of the
United States Department of Health and
Human Services and is responsible for regulating and
supervising the safety of
foods,
dietary supplements,
drugs,
vaccines,
biological medical products,
blood products,
medical devices,
radiation-emitting devices,
veterinary products, and
cosmetics) has insisted that the
drug has a stronger Risk Management Programme than used in the past.
The
new
Risk Management Programme is called
iPLEDGE
VIDEO
(Please click on symbol below to view video)
BEHÇET’S SYNDROME SOCIETY
Behçet’s Introduction
Behçet’s syndrome, (now known as Behçet’s disease), is a
chronic condition which happens because of disturbances in
the body’s immune system. This system, which normally
protects the body against infections by producing controlled
inflammation, becomes over-active and produces unpredictable
out-breaks of unwanted and exaggerated inflammation. This
extra inflammation affects blood vessels, usually the small
ones. As a result, symptoms occur wherever there is a patch
of inflammation, and can be anywhere where there is a blood
supply.
No one knows why the immune system starts to behave this way
in Behçet’s disease. It is not because of any known
infections, it is not hereditary, it is not to do with
ethnic origin, gender, life-style, age, where someone has
lived or where they have been on holiday. It is not
associated with cancer, and links with tissue-types (which
are under investigation) are not certain. It does not follow
the usual pattern for auto-immune diseases. Now it is
defined as being a disease of inflamed blood vessels (vasculitis)
- a ‘vasculitic’ disease.
Although Behçet’s disease is incurable at present, incurable
does not mean untreatable. There are several ways in which
the immune system can be suppressed to an appropriate level
to reduce the extra inflammation, and this suppresses the
symptoms.
Most of the symptoms are painful but not life-threatening.
They come and go in a series of attacks (‘flare-ups’)
throughout life. The disease does not ‘burn itself out’ but
sometimes it can level off and the flare-ups become less
aggressive and happen less frequently. Most people with
Behçet’s disease have a normal life-span and can hope to
lead close-to-normal daily lives.
No-one knows for sure how many sufferers there are in the UK
but it is estimated that there are about 2 in 100,000, that
is, about 2000 people. It is much less rare in the Middle
East and in Asia. Because it seems to be prevalent in the
areas surrounding the old silk trading routes, it is
sometimes known as the 'Silk Route' disease.
|
